At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
In Brief
A Phase 2 clinical trial evaluating APX3330 and Placebo for Diabetic Retinopathy and 3 related conditions. Completed, enrolled 103 participants across 24 sites.
Signals
Detailed Summary
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
Study Details
Timeline
Arms & Interventions
Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
Five 120 mg tablets will be taken by mouth as follows: 3 tablets every morning and 2 tablets every evening.
Interventions
APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.